​

Pfizer (PFE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PFE Stock Forecast

Pfizer (PFE) stock forecast, based on 39 Wall Street analysts, predicts a 12-month average price target of $27.50, with a high of $35.00 and a low of $24.00. This represents a -2.93% decline from the last price of $28.33.

$20 $23 $26 $29 $32 $35 High: $35 Avg: $27.5 Low: $24 Last Closed Price: $28.33

PFE Stock Rating

Pfizer stock's rating consensus is Hold, based on 39 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (41.03%), 22 Hold (56.41%), 1 Sell (2.56%), and 0 Strong Sell (0.00%).

Hold
Total 39 1 22 16 Strong Sell Sell Hold Buy Strong Buy

PFE Price Target Upside V Benchmarks

TypeNameUpside
StockPfizer-2.93%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks5.56%

Price Target Trends

1M3M12M
# Anlaysts2716
Avg Price Target$28.50$26.57$27.63
Last Closing Price$28.33$28.33$28.33
Upside/Downside0.60%-6.21%-2.47%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2628151228
Mar, 2628151228
Feb, 2637151-26
Jan, 2637151-26
Dec, 2537151-26
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 17, 2026Terence FlynnMorgan Stanley$27.00$27.06-0.22%-4.69%
Mar 09, 2026Evan David SeigermanBMO Capital$30.00$26.4913.25%5.89%
Feb 24, 2026Trung HuynhRBC Capital$25.00$27.14-7.89%-11.75%
Feb 19, 2026Emily FieldBarclays$25.00$26.86-6.92%-11.75%
Feb 12, 2026Narumi NakagiriDaiwa$27.00$27.73-2.63%-4.69%
Jan 27, 2026Cantor Fitzgerald$27.00$25.884.33%-4.69%
Jan 06, 2026UBS$25.00$25.43-1.69%-11.75%
Dec 17, 2025Alexandria HammondWolfe Research$24.00$25.53-5.99%-15.28%
Dec 12, 2025Morgan Stanley$28.00$25.898.15%-1.16%
Dec 10, 2025Rajesh KumarHSBC$29.00$25.3314.49%2.36%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 17, 2026Morgan StanleyPositivePositivehold
Mar 09, 2026BMO CapitalOutperformOutperformhold
Feb 24, 2026RBC CapitalSector PerformUnderperforminitialise
Feb 19, 2026BarclaysEqual-WeightUnderweightinitialise
Feb 12, 2026DaiwaOutperformNeutraldowngrade
Jan 27, 2026Cantor FitzgeraldNeutralNeutralhold
Dec 30, 2025Cowen & Co.HoldHoldhold
Dec 17, 2025GuggenheimBuyBuyhold
Dec 17, 2025Wolfe ResearchUnderperformUnderperformhold
Dec 16, 2025Bank of America SecuritiesNeutralNeutralhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.95$5.59$0.38$1.42$1.36---
Avg Forecast$4.21$6.50$1.55$2.92$2.91$3.01$2.98$2.85
High Forecast$4.35$6.64$1.66$3.12$3.03$3.92$3.37$2.91
Low Forecast$4.06$6.29$1.48$2.73$2.46$2.58$2.24$2.77
Surprise %-6.18%-14.00%-75.48%-51.37%-53.26%---

Revenue Forecast

$55B $65B $75B $85B $95B $105B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$81.29B$100.33B$59.55B$63.63B$62.58B---
Avg Forecast$81.76B$100.34B$58.78B$63.08B$63.08B$63.06B$62.33B$59.90B
High Forecast$83.89B$101.97B$59.18B$63.63B$63.93B$63.14B$62.50B$60.82B
Low Forecast$79.56B$97.80B$58.53B$62.67B$62.46B$62.99B$62.17B$58.66B
Surprise %-0.58%-0.01%1.32%0.87%-0.79%---

Net Income Forecast

$0 $7B $14B $21B $28B $35B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$22.15B$31.36B$2.13B$8.02B$7.77B---
Avg Forecast$24.02B$18.44B$2.13B$16.71B$15.66B$18.56B$12.93B$16.27B
High Forecast$24.84B$22.12B$2.56B$17.81B$17.30B$22.37B$19.23B$16.59B
Low Forecast$23.18B$14.75B$1.71B$15.60B$14.02B$14.75B$12.79B$15.83B
Surprise %-7.82%70.12%-0.05%-52.00%-50.38%---

PFE Forecast FAQ

Is Pfizer stock a buy?

Pfizer stock has a consensus rating of Hold, based on 39 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 22 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Pfizer is a neutral investment for most analysts.

What is Pfizer's price target?

Pfizer's price target, set by 39 Wall Street analysts, averages $27.5 over the next 12 months. The price target range spans from $24 at the low end to $35 at the high end, suggesting a potential -2.93% change from the previous closing price of $28.33.

How does Pfizer stock forecast compare to its benchmarks?

Pfizer's stock forecast shows a -2.93% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the drug manufacturers - general stocks industry (5.56%).

What is the breakdown of analyst ratings for Pfizer over the past three months?

  • April 2026: 7.14% Strong Buy, 28.57% Buy, 53.57% Hold, 3.57% Sell, 7.14% Strong Sell.
  • March 2026: 7.14% Strong Buy, 28.57% Buy, 53.57% Hold, 3.57% Sell, 7.14% Strong Sell.
  • February 2026: 11.54% Strong Buy, 26.92% Buy, 57.69% Hold, 3.85% Sell, 0% Strong Sell.

What is Pfizer’s EPS forecast?

Pfizer's average annual EPS forecast for its fiscal year ending in December 2026 is $3.01, marking a 121.32% increase from the reported $1.36 in 2025. Estimates for the following years are $2.98 in 2027, and $2.85 in 2028.

What is Pfizer’s revenue forecast?

Pfizer's average annual revenue forecast for its fiscal year ending in December 2026 is $63.06B, reflecting a 0.78% increase from the reported $62.58B in 2025. The forecast for 2027 is $62.33B, and $59.9B for 2028.

What is Pfizer’s net income forecast?

Pfizer's net income forecast for the fiscal year ending in December 2026 stands at $18.56B, representing an 138.90% increase from the reported $7.77B in 2025. Projections indicate $12.93B in 2027, and $16.27B in 2028.